- Home
- JFR vs HROW Comparison
JFR vs HROW Comparison
Compare JFR & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFR
- HROW
- Stock Information
- Founded
- JFR 2004
- HROW 1998
- Country
- JFR United States
- HROW United States
- Employees
- JFR N/A
- HROW N/A
- Industry
- JFR Trusts Except Educational Religious and Charitable
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- JFR Finance
- HROW Health Care
- Exchange
- JFR Nasdaq
- HROW Nasdaq
- Market Cap
- JFR 1.3B
- HROW 1.4B
- IPO Year
- JFR N/A
- HROW N/A
- Fundamental
- Price
- JFR $7.90
- HROW $37.77
- Analyst Decision
- JFR
- HROW Strong Buy
- Analyst Count
- JFR 0
- HROW 7
- Target Price
- JFR N/A
- HROW $68.50
- AVG Volume (30 Days)
- JFR 621.7K
- HROW 765.0K
- Earning Date
- JFR 01-01-0001
- HROW 11-10-2025
- Dividend Yield
- JFR 11.31%
- HROW N/A
- EPS Growth
- JFR N/A
- HROW N/A
- EPS
- JFR N/A
- HROW N/A
- Revenue
- JFR N/A
- HROW $227,661,000.00
- Revenue This Year
- JFR N/A
- HROW $43.92
- Revenue Next Year
- JFR N/A
- HROW $41.22
- P/E Ratio
- JFR N/A
- HROW N/A
- Revenue Growth
- JFR N/A
- HROW 47.69
- 52 Week Low
- JFR $7.61
- HROW $20.85
- 52 Week High
- JFR $8.82
- HROW $54.19
- Technical
- Relative Strength Index (RSI)
- JFR 40.23
- HROW 41.94
- Support Level
- JFR $7.84
- HROW $36.20
- Resistance Level
- JFR $8.15
- HROW $39.77
- Average True Range (ATR)
- JFR 0.06
- HROW 1.92
- MACD
- JFR 0.02
- HROW -0.29
- Stochastic Oscillator
- JFR 57.30
- HROW 25.70
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.